Duncan-Williams Initiates Coverage on Kensey Nash (KNSY) with a Buy; Significant Future Growth in Cardiac Care & Orthopedic Markets
More News related to KNSY
- Kensey Nash (KNSY) Receives FDA Clearance for its First Extracellular Matrix Product, Medeor
- Kensey Nash Receives FDA 510(k) Clearance for Porcine Dermis Biologic Product
- Kensey Nash (KNSY) Posts Q1 EPS of $0.43; GUides
- Kensey Nash Reports First Quarter Fiscal Year 2010 Financial Results
- Trading Radar for 10/22: AT&T (T), McDonalds (MCD), Amazon.com (AMZN), 3M (MMM), Dow Chemical (DOW), UPS (UPS) Report
More News related to New Coverage
- Human Genome Sciences (HGSI) To Offer Up to 12.5M Shares
- ZymoGenetics (ZGEN) Higher Ahead of Presentation
- Somaxon Pharmaceuticals (SOMX) Surges Ahead of FDA Action Date
- BioMarin Pharmaceutical (BMRN) Announces FDA Grants Orphan Drug Designation for 3,4-DAP
- FDA Approves Cymbalta (LLY) for Treatment of Generalized Anxiety Disorder
Duncan-Williams initiates coverage on Kensey Nash Corporation (Nasdaq: KNSY) with a Buy.
Duncan analyst says, "Kensey Nash is a leader in developing, manufacturing and processing resorbable biomaterial products, incorporating its proprietary collagen and synthetic polymer technology. This expertise is used to develop and commercialize its products through strategic partners. The company has an extensive range of products, which are sold in multiple medical markets, including, the cardiology, orthopedic, sports medicine, spine, endovascular, and general surgery markets...We estimate that both the cardiac care and orthopedic markets are positioned for significant future growth driven by the Aging of the Population."
"KNSY continues to leverage their technology and expertise to develop new proprietary biomaterial products. KNSY works with strategic partners or clinicians as they identify new bioresorbable products...KNSY continues to seek strategic acquisitions and alliances that add new and complementary technologies and expertise, broaden their intellectual property portfolio, and strengthen their competitive position in the biomaterials business...Strong balance sheet: At 6/30/2009, KNSY had cash and investments of $79.7 million. Total current assets were $105.2 million with total assets of $171.1 million."
To see more analyst ratings on KNSY Click Here.
Kensey Nash Corporation, a medical device company, develops products and technologies in the fields of resorbable biomaterials and endovascular devices used in various medical procedures.
Related Categories
New CoverageStocks Mentioned
-0.57Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
